Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC

ConclusionsHigh CD73 expression may predict a favorable response to ICIs in NSCLC patients, especially those harboringEGFR mutations.Key pointsSignificant findings of the study: In patients who were positive for EGFR mutation, immune checkpoint inhibitors (ICIs) were significantly more effective in those with high CD73 expression, whereas CD73 expression did not significantly affect the efficacy in patients with EGFR mutation ‐negative NSCLC.What this study adds: High CD73 expression may predict a favorable response to immune checkpoint inhibitors in NSCLC patients, especially those harboring EGFR mutations.

Source: Thoracic Cancer - February 16, 2020 Category: Cancer & Oncology Authors: Hidenobu Ishii, Koichi Azuma, Akihiko Kawahara, Takashi Kinoshita, Norikazu Matsuo, Yoshiko Naito, Takaaki Tokito, Kazuhiko Yamada, Jun Akiba, Tomoaki Hoshino Tags: ORIGINAL ARTICLE Source Type: research